News Release

Dr. Ying Luo, CEO of GNI Group Ltd., gave a presentation on “From lung fibrosis to liver fibrosis” at the “NASH and Fibrosis” track of Discovery on Target conference in Boston MA, USA on September 27, 2017.

During the presentation, he summarized the past study results from animal models of lung, kidney, cardiac, and liver fibrosis. Also discussed the safety data of the finished Phase I study. We believe F351 is more potent and safer than Etuary. He also reported the progress of current Phase II study. Phase II study has not been concluded yet.